Structure

InChI Key HJBWBFZLDZWPHF-UHFFFAOYSA-N
Smile CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
InChI
InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H15F4N5O2S
Molecular Weight 477.44
AlogP 3.53
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 89.33
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Androgen Receptor antagonist PubMed Other
Primary Target
Androgen receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 4 D064129 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 4 D064129 FDA
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials

Related Entries

MCS

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
19.03
Nervous system disorders
10.57
Skin and subcutaneous tissue disorders
10.57
Gastrointestinal disorders
9.44
Cardiac disorders
6.27
Vascular disorders
6.27
Investigations
5.66
Musculoskeletal and connective tissue disorders
5.06
Injury, poisoning and procedural complications
4.61
Respiratory, thoracic and mediastinal disorders
3.7
Psychiatric disorders
3.63
Surgical and medical procedures
2.95
Metabolism and nutrition disorders
2.79

Cross References

Resources Reference
CAS NUMBER 956104-40-8
ChEMBL CHEMBL3183409
DrugBank DB11901
DrugCentral 5278
EPA CompTox DTXSID40241899
FDA SRS 4T36H88UA7
Guide to Pharmacology 9043
PubChem 24872560
SureChEMBL SCHEMBL909297
ZINC ZINC000043174901